Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
about
Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscleSpatiotemporal control over growth factor signaling for therapeutic neovascularizationVascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb modelTransmyocardial revascularization devices: technology updateStem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?Therapeutic angiogenesis: controlled delivery of angiogenic factors.SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular diseaseFibroblast growth factors in cardiovascular disease: The emerging role of FGF21Clinical translation of controlled protein delivery systems for tissue engineeringCurrent medical management of chronic stable anginaFibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular developmentLoss of glypican-3 function causes growth factor-dependent defects in cardiac and coronary vascular developmentMechanisms of Amplified Arteriogenesis in Collateral Artery Segments Exposed to Reversed Flow Direction.Computational Network Model Prediction of Hemodynamic Alterations Due to Arteriolar Rarefaction and Estimation of Skeletal Muscle Perfusion in Peripheral Arterial Disease.Applications of computational models to better understand microvascular remodelling: a focus on biomechanical integration across scales.Systems biology of pro-angiogenic therapies targeting the VEGF systemMechanistic exploration of phthalimide neovascular factor 1 using network analysis tools.Expansion of microvascular networks in vivo by phthalimide neovascular factor 1 (PNF1)Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis.Therapeutic angiogenesis for critical limb ischaemia.Myoglobin overexpression inhibits reperfusion in the ischemic mouse hindlimb through impaired angiogenesis but not arteriogenesis.Hedgehog signaling is critical for maintenance of the adult coronary vasculature in miceVirus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?Angiogenic therapy for coronary artery and peripheral arterial disease.Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial.Adeno associated viral vector-delivered and hypoxia response element-regulated CD151 expression in ischemic rat heart.Pharmacotherapy for end-stage coronary artery disease.Endothelial nitric oxide synthase affects both early and late collateral arterial adaptation and blood flow recovery after induction of hind limb ischemia in mice.VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trialImproved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.Therapeutic angiogenesis in diabetes and hypercholesterolemia: influence of oxidative stress.FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes.The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering ApplicationsCoupling growth-factor engineering with nanotechnology for therapeutic angiogenesis.Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis.Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardiumTissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function.Blood vessel repair and regeneration in the ischaemic heartNatural aminoacyl tRNA synthetase fragment enhances cardiac function after myocardial infarction.Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)
P2860
Q24633567-2163AD32-93EB-488A-A942-C547073BEE0BQ24641819-5B6EF3C8-7F98-4212-B6E6-BFACF6E87312Q24807288-D2F3F9D7-F846-4565-8D32-CFCC28BF5591Q26865489-B3BDCDD4-BA52-4F2E-9AC9-048E51EF3331Q27022877-F8001728-9B29-4CA7-B481-0450D5B9CF01Q27023731-A545301A-E036-4F88-A6B9-149A86AE83AEQ28066121-EDDEF6F0-B387-41B7-8795-144A3B8D92B6Q28084197-666C7DC7-9200-4F66-A00E-D29128F5364BQ28084738-5A8618AA-CF8C-47B2-81EB-B3684D9F7EB1Q28213164-8215AE34-4780-4543-A01C-B2DDCFF6A5D5Q28511544-2F3F0470-6D72-4075-BF20-DB6B1C180F1FQ28587262-17C856B5-7C5E-44F1-B253-3DD1D927F6D4Q30278752-2F52C3A8-74A2-4899-A740-13D5D90BBCF0Q30300196-29F21899-E64A-4970-8CCA-5E71DFFD72D8Q30300240-D0823290-BB4E-4F32-922C-164BAB4E6740Q30430112-70E5D517-6FFE-4B1E-B59D-FBCF580E56CFQ30431758-C72C07AB-4486-4D19-99CB-76D4D475887DQ30435865-53746FAE-0E4D-4B5C-8F28-E453D322709BQ30438396-77C08148-70F8-457A-B85A-9C632800DC54Q30456666-D41AD365-3AA6-42A1-9E27-7010A1965AD0Q30457043-99689CE4-E1C3-481C-8F46-903C8CAAECDDQ30482359-5FF3BC56-F7BC-42E7-9124-222FEAE64F39Q30489689-AB49E822-D10A-4828-A58B-323928CD1CD6Q30783593-108D1474-9E54-477F-8F41-F287D4FE5DA9Q33198730-5CC42762-975A-4775-83B3-7DF4D3E2F412Q33565700-F5C27AEC-037A-47F9-9C99-A0BFD56067C2Q33610142-20094483-8CA2-4286-A273-F85968D1D9EFQ33625831-764A8D8C-FD53-48D2-8A0F-BBDCBB926C7BQ33713721-CA15CF58-9A64-4590-B7CA-790A36132C7BQ33759629-B18463E0-7934-456D-B372-3CCCEB26EDCAQ33765479-812488FC-D8D3-48B4-A12C-04F047A3724FQ33842934-CD35DCB9-5EFA-4787-859F-E4D432D8132FQ33851544-2FDBEC98-BAD0-4FBC-9F83-C12796C5ADF3Q34068511-E3CDBC82-BCED-4D84-8466-3AF28F953EA9Q34074910-8F145413-92A8-42D5-9094-E06D3882CC05Q34134323-D13043AA-6CEC-41FD-8A07-0E2B44C1754DQ34140406-7D6B9B6D-0E10-4D08-BDB8-ADA3A3DA72A8Q34304413-A7D48894-0B65-4582-B881-FD1533490AF3Q34308682-8656DF01-3528-4861-81C8-7FE9A8E050BCQ34312563-AFF5B1F7-EF4D-4C11-B199-956458F74C14
P2860
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Pharmacological treatment of c ...... ed, controlled clinical trial.
@en
type
label
Pharmacological treatment of c ...... ed, controlled clinical trial.
@en
prefLabel
Pharmacological treatment of c ...... ed, controlled clinical trial.
@en
P2093
P356
P1433
P1476
Pharmacological treatment of c ...... ed, controlled clinical trial.
@en
P2093
Brian H Annex
Ernesto V Gervino
Harold Dauerman
James E Udelson
M J Whitehouse
Marilyn Pike
Michael Simons
Neal Kleiman
Nicolas A Chronos
Roger J Laham
P304
P356
10.1161/HC0802.104407
P407
P577
2002-02-01T00:00:00Z